Lantheus Holdings Inc (NASDAQ:LNTH) was the recipient of a significant decline in short interest during the month of June. As of June 30th, there was short interest totalling 950,900 shares, a decline of 9.6% from the May 30th total of 1,051,400 shares. Approximately 2.6% of the shares of the stock are short sold. Based on an average daily volume of 404,500 shares, the short-interest ratio is presently 2.4 days.
LNTH has been the subject of several research analyst reports. Zacks Investment Research lowered GenMark Diagnostics from a “hold” rating to a “sell” rating in a research note on Wednesday, April 24th. BidaskClub lowered Xencor from a “sell” rating to a “strong sell” rating in a research note on Tuesday, June 11th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $23.33.
Shares of NASDAQ LNTH traded up $0.10 during midday trading on Friday, reaching $27.76. The company had a trading volume of 354,498 shares, compared to its average volume of 404,008. Lantheus has a one year low of $12.59 and a one year high of $29.80. The company has a debt-to-equity ratio of 3.16, a quick ratio of 3.82 and a current ratio of 4.57. The company’s fifty day simple moving average is $26.58. The company has a market cap of $1.08 billion, a PE ratio of 29.53, a PEG ratio of 2.08 and a beta of 1.49.
Lantheus (NASDAQ:LNTH) last released its earnings results on Tuesday, April 30th. The medical equipment provider reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.03. Lantheus had a return on equity of 59.57% and a net margin of 12.17%. The company had revenue of $86.51 million during the quarter, compared to analyst estimates of $86.80 million. As a group, research analysts anticipate that Lantheus will post 1.11 earnings per share for the current fiscal year.
In other Lantheus news, Director Brian A. Markison sold 5,000 shares of Lantheus stock in a transaction dated Tuesday, April 23rd. The stock was sold at an average price of $24.07, for a total transaction of $120,350.00. Following the completion of the sale, the director now owns 87,467 shares of the company’s stock, valued at $2,105,330.69. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Mary Anne Heino sold 29,813 shares of Lantheus stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $24.86, for a total value of $741,151.18. Following the sale, the chief executive officer now directly owns 654,589 shares of the company’s stock, valued at approximately $16,273,082.54. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 202,908 shares of company stock valued at $5,254,409. Corporate insiders own 2.60% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in LNTH. PNC Financial Services Group Inc. lifted its stake in shares of Lantheus by 51.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,694 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 575 shares during the last quarter. Advisor Group Inc. lifted its stake in shares of Lantheus by 1,837.2% in the 4th quarter. Advisor Group Inc. now owns 4,378 shares of the medical equipment provider’s stock valued at $69,000 after acquiring an additional 4,152 shares during the last quarter. First Quadrant L P CA bought a new stake in shares of Lantheus in the 1st quarter valued at about $95,000. Anderson Fisher LLC bought a new stake in shares of Lantheus in the 1st quarter valued at about $112,000. Finally, Meeder Asset Management Inc. lifted its stake in shares of Lantheus by 212.8% in the 1st quarter. Meeder Asset Management Inc. now owns 4,757 shares of the medical equipment provider’s stock valued at $115,000 after acquiring an additional 3,236 shares during the last quarter. 92.55% of the stock is owned by institutional investors.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.
Featured Story: What is a stock portfolio tracker?
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.